ND | HD | PD | |
---|---|---|---|
Treatment-naïve patients | |||
N | 678 | 111 | 66 |
Response rate†, n (%; 95% CI) | 441 (65.04; 61.32–68.63) | 60 (54.05; 44.33–63.55) | 51 (77.27; 65.30–86.68) |
No effect, n (%) | 237 (34.95) | 51 (45.94) | 15 (22.72) |
Patients switched from EPO | |||
N | 160 | 399 | 20 |
Response rate‡, n (%; 95% CI) | 109 (68.12; 60.30–75.25) | 279 (69.92; 65.16–74.38) | 12 (60.00; 36.05–80.88) |
No effect, n (%) | 51 (31.87) | 120 (30.07) | 8 (40.00) |
Patients switched from DA | |||
N | 265 | 383 | 146 |
Response rate†, n (%; 95% CI) | 162 (61.13; 54.97–67.03) | 256 (66.84; 61.87–71.53) | 99 (67.80; 59.58–75.29) |
No effect, n (%) | 103 (38.86) | 127 (33.15) | 47 (32.19) |